These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 35603410)

  • 21. A review of immune checkpoint blockade in breast cancer.
    Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
    Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic tagging to drive arginine nano-assembly to metabolically potentiate immune checkpoint blockade therapy.
    Zang J; Yang Y; Zheng X; Yang Y; Zhao Y; Miao Z; Zhang T; Gu J; Liu Y; Yin W; Ma X; Ding Q; Dong H; Li Y; Li Y
    Biomaterials; 2023 Jan; 292():121938. PubMed ID: 36493715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
    Liu Z; Xiang Y; Zheng Y; Kang X
    Front Immunol; 2022; 13():1027124. PubMed ID: 36341334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.
    Zhang Y; Chen X; Hu B; Zou B; Xu Y
    Nanomedicine (Lond); 2024; 19(21-22):1821-1840. PubMed ID: 39011582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
    Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
    Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
    Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
    J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
    Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
    J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
    Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
    Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy.
    Zhang MR; Fang LL; Guo Y; Wang Q; Li YJ; Sun HF; Xie SY; Liang Y
    Int J Nanomedicine; 2024; 19():3387-3404. PubMed ID: 38617801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy.
    Ma GL; Lin WF
    Mil Med Res; 2023 Apr; 10(1):20. PubMed ID: 37106400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.
    Heinhuis KM; Ros W; Kok M; Steeghs N; Beijnen JH; Schellens JHM
    Ann Oncol; 2019 Feb; 30(2):219-235. PubMed ID: 30608567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy.
    Xu W; Liu W; Yang J; Lu J; Zhang H; Ye D
    Immunol Rev; 2024 Jan; 321(1):181-198. PubMed ID: 37403660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy.
    Lin RA; Lin JK; Lin SY
    Kaohsiung J Med Sci; 2021 Jun; 37(6):448-458. PubMed ID: 33636043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifunctional Nano-Biomaterials for Cancer Therapy via Inducing Enhanced Immunogenic Cell Death.
    Chen Q; Li C; Wang Q
    Small Methods; 2023 May; 7(5):e2201457. PubMed ID: 36703555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Nanophotoimmunotherapy Potentiates Cancer Treatment by Enhancing Tumor Immunogenicity and Improving the Immunosuppressive Tumor Microenvironment.
    Li K; Yang D; Liu D
    Bioconjug Chem; 2023 Feb; 34(2):283-301. PubMed ID: 36648963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential role of vitamin C in empowering cancer immunotherapy.
    Bedhiafi T; Inchakalody VP; Fernandes Q; Mestiri S; Billa N; Uddin S; Merhi M; Dermime S
    Biomed Pharmacother; 2022 Feb; 146():112553. PubMed ID: 34923342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.